LEGN

Legend Biotech Corporation (LEGN) reported Q4 2025 adjusted earnings of $0.01 per share. No consensus estimate was available for comparison.…

Legend Biotech posts $0.01 adjusted EPS in Q4 2025, turning profitable on 64% revenue growth to $306.3M as commercial momentum…

Legend Biotech (NASDAQ: LEGN) reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting continued…

Legend Biotech Corporation (NASDAQ: LEGN) Q4 2020 Earnings Conference